Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01905124
Other study ID # CF101-241UV
Secondary ID
Status Withdrawn
Phase Phase 2
First received July 14, 2013
Last updated January 30, 2018
Start date January 2019
Est. completion date October 2019

Study information

Verified date January 2018
Source Can-Fite BioPharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.


Description:

This is a Phase 2, randomized, double-masked, placebo-controlled study in adult males and females, aged 18 years and over, with active, sight-threatening, noninfectious intermediate or posterior uveitis. Subjects will be randomly assigned to receive CF101 1 mg or matching placebo tablets in a 2:1 ratio orally every 12 hours for 24 weeks.

At the Screening Visit (performed within 4 weeks prior to Baseline), subjects who provide written informed consent will have a complete medical history, medication history, physical examination, weight, sitting blood pressure, pulse rate, temperature, electrocardiogram (ECG), clinical laboratory tests, and ophthalmologic examination, including biomicroscopy and grading of uveitis activity. For assessment of uveitis activity and response to treatment, fundus photography will be obtained according to a standardized procedure and interpreted at the Uveitis Photograph Reading Center.

Subjects who successfully qualify will begin dosing with CF101 1 mg or placebo, to be taken orally every 12 hours for 24 weeks. At the Baseline Visit, a PBMC sample will be obtained for assessment of A3AR expression level. Subjects will return for safety and efficacy assessments and a new supply of study medication at Weeks 2, 4, 8, 12, 16, 20, and for final assessment and discharge at Week 24. A telephone call to each subject will be made at Week 26, for the purpose of collecting information on adverse events (AEs) and concomitant medications.

During the course of the trial, concomitant use of intraocular or posterior subtenon corticosteroids, intravitreal injections (including but not limited to steroids or anti-vascular endothelial growth factors), systemic corticosteroids at a dose >20 mg/day prednisone equivalent, or monoclonal antibody therapy is prohibited. Systemic corticosteroid and immunosuppressive regimens must remain stable throughout the course of the trial.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date October 2019
Est. primary completion date September 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female, 18 years of age and over;

2. Diagnosis of active, sight-threatening, noninfectious intermediate or posterior uveitis, as determined by the Standardization of Uveitis Nomenclature (SUN) Working Group Criteria.

3. Vitreous haze in at least 1 eye (the "study eye") of =Grade 3 on the "Miami Scale" at the Screening Visit, as confirmed by the Uveitis Photograph Reading Center; ,

4. Best corrected visual acuity (BCVA) in the poorer seeing eye of 1.3 logarithm of the minimum angle of resolution (logMAR) or better by Early Treatment Diabetic Retinopathy Study (ETDRS; equivalent to 20/400) at Screening;

5. Requires, in the judgment of the Investigator, systemic therapy to treat uveitis;

6. No plans for elective ocular surgery during the trial duration;

10. Ability to understand and provide written informed consent.

Exclusion Criteria:

1. Primary diagnosis of anterior uveitis;

2. Uveitis of infectious etiology;

3. Presence of chorioretinal scars that are highly suspicious for ocular toxoplasmosis;

4. Confirmed or suspected uveitis of traumatic etiology;

5. Clinically suspected or confirmed central nervous system or ocular lymphoma;

6. Presence of any other form of ocular malignancy in the either eye including choroidal melanoma;

7. Corneal or lens opacities or obscured ocular media other than vitreous haze upon enrollment such that reliable clinical evaluations and grading of the posterior segment cannot be performed;

8. Pupillary dilation inadequate for quality fundus photography;

9. Uncontrolled glaucoma or ocular hypertension in either eye, defined as intraocular pressure (IOP) >21 mm Hg while on medical therapy;

10. Chronic hypotony (IOP <6 mm Hg) in either eye;

11. Presence of an ocular implantable steroid-eluting device;

12. Ocular injection of corticosteroid within 3 months prior to Baseline;

13. Use of Retisert within 6 months prior to baseline;

14. Use of the following within 90 days prior to Baseline or anticipated use to either eye during the trial:

1. Intravitreal injections (including but not limited to steroids or anti-vascular endothelial growth factors), or

2. Posterior subtenon steroids;

15. YAG capsulotomy within 30 days prior to Day 1 in the study eye;

16. History of herpetic infection in the study eye or adnexa;

17. Oral corticosteroid dose >20 mg/day prednisone equivalent;

18. Oral corticosteroid dose has been changed within 2 weeks prior to screening, or is expected to change while on study;

19. Systemic immunosuppressive agent dose has been changed within 2 weeks prior to screening;

20. Treatment with systemic monoclonal antibody within the longer of 1 month or 5 serum half-lives, prior to screening;

21. Diagnosis or history of Behçet's Disease;

22. Any significant ocular disease that could compromise vision in either eye, including but not limited to:

1. Diabetic retinopathy: proliferative diabetic retinopathy or non-proliferative diabetic retinopathy that compromise vision,

2. Wet age-related macular degeneration, and

3. Myopic degeneration with active subfoveal choroidal neovascularization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CF101
CF101 1 mg tablets orally every 12 hours for 24 weeks
Placebo
Matching placebo tablets orally every 12 hours for 24 weeks

Locations

Country Name City State
Israel Bnei-Zion Medical Center Haifa

Sponsors (1)

Lead Sponsor Collaborator
Can-Fite BioPharma

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity of uveitis on standardized photographic assessment Standardized fundus photographs will be obtained and uniformly assessed in a masked fashion at the Reading Center 24 weeks
Secondary Safety of CF101 Frequency, nature, and severity of adverse events 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT00570479 - Prophylactic Anecortave Acetate in Patients With a Retisert Implant Phase 1
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Terminated NCT03656692 - Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) Phase 4
Completed NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Phase 2
Completed NCT00035906 - Research Study in Patients With Persistent Macular Edema Phase 2
Recruiting NCT05101928 - Ozurdex Monotherapy Trial Phase 4
Terminated NCT05070728 - Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) Phase 3
Completed NCT02595398 - Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Phase 3
Recruiting NCT03066869 - Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Phase 4
Completed NCT01539577 - A Long-Term Safety Study of OZURDEX® in Clinical Practice N/A
Recruiting NCT05322070 - Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis Phase 4
Recruiting NCT06085079 - Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Phase 4
Completed NCT03145025 - Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Completed NCT03598452 - High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients N/A
Completed NCT02049476 - Study of the Effectiveness of Ozurdex for the Control of Uveitis Phase 4
Completed NCT00404612 - A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Phase 3
Completed NCT00404742 - A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Phase 3
Completed NCT02952001 - MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Not yet recruiting NCT06431373 - A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Phase 3
Completed NCT03097315 - Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase 3